These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21933139)

  • 1. Muscle metabolism and exercise capacity in cachexia.
    Adams V; Anker SD; Schuler G
    Curr Pharm Des; 2011 Dec; 17(35):3838-45. PubMed ID: 21933139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: potential therapeutic targets for cardiac cachexia.
    Yoshida T; Tabony AM; Galvez S; Mitch WE; Higashi Y; Sukhanov S; Delafontaine P
    Int J Biochem Cell Biol; 2013 Oct; 45(10):2322-32. PubMed ID: 23769949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia.
    Melstrom LG; Melstrom KA; Ding XZ; Adrian TE
    Histol Histopathol; 2007 Jul; 22(7):805-14. PubMed ID: 17455154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Systemic and local mechanisms leading to cachexia in cancer].
    Grabiec K; Burchert M; Milewska M; Błaszczyk M; Grzelkowska-Kowalczyk K
    Postepy Hig Med Dosw (Online); 2013 Dec; 67():1397-409. PubMed ID: 24493689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the anticatabolic effects of leucine and Ca-β-hydroxy-β-methylbutyrate in experimental models of cancer cachexia.
    Mirza KA; Pereira SL; Voss AC; Tisdale MJ
    Nutrition; 2014; 30(7-8):807-13. PubMed ID: 24984997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II as candidate of cardiac cachexia.
    Delafontaine P; Akao M
    Curr Opin Clin Nutr Metab Care; 2006 May; 9(3):220-4. PubMed ID: 16607120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system.
    Op den Kamp CM; Langen RC; Minnaard R; Kelders MC; Snepvangers FJ; Hesselink MK; Dingemans AC; Schols AM
    Lung Cancer; 2012 Apr; 76(1):112-7. PubMed ID: 22018880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of Cachexia in Chronic Disease States.
    Yoshida T; Delafontaine P
    Am J Med Sci; 2015 Oct; 350(4):250-6. PubMed ID: 26083652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Waste management - cytokines, growth factors and cachexia.
    Saini A; Al-Shanti N; Stewart CE
    Cytokine Growth Factor Rev; 2006 Dec; 17(6):475-86. PubMed ID: 17118696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of PARP activity in lung cancer-induced cachexia: Effects on muscle oxidative stress, proteolysis, anabolic markers, and phenotype.
    Chacon-Cabrera A; Mateu-Jimenez M; Langohr K; Fermoselle C; García-Arumí E; Andreu AL; Yelamos J; Barreiro E
    J Cell Physiol; 2017 Dec; 232(12):3744-3761. PubMed ID: 28177129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial uncoupling reduces exercise capacity despite several skeletal muscle metabolic adaptations.
    Schlagowski AI; Singh F; Charles AL; Gali Ramamoorthy T; Favret F; Piquard F; Geny B; Zoll J
    J Appl Physiol (1985); 2014 Feb; 116(4):364-75. PubMed ID: 24336883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aerobic exercise training as therapy for cardiac and cancer cachexia.
    Alves CR; da Cunha TF; da Paixão NA; Brum PC
    Life Sci; 2015 Mar; 125():9-14. PubMed ID: 25500304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mitochondrial metabolic reprogramming agent trimetazidine as an 'exercise mimetic' in cachectic C26-bearing mice.
    Molinari F; Pin F; Gorini S; Chiandotto S; Pontecorvo L; Penna F; Rizzuto E; Pisu S; Musarò A; Costelli P; Rosano G; Ferraro E
    J Cachexia Sarcopenia Muscle; 2017 Dec; 8(6):954-973. PubMed ID: 29130633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myostatin/activin pathway antagonism: molecular basis and therapeutic potential.
    Han HQ; Zhou X; Mitch WE; Goldberg AL
    Int J Biochem Cell Biol; 2013 Oct; 45(10):2333-47. PubMed ID: 23721881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the beta
    Salazar-Degracia A; Busquets S; Argilés JM; Bargalló-Gispert N; López-Soriano FJ; Barreiro E
    Biochimie; 2018 Jun; 149():79-91. PubMed ID: 29654866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer cachexia: molecular targets and pathways for diagnosis and drug intervention.
    Shum AM; Polly P
    Endocr Metab Immune Disord Drug Targets; 2012 Sep; 12(3):247-59. PubMed ID: 22385113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linking Cancer Cachexia-Induced Anabolic Resistance to Skeletal Muscle Oxidative Metabolism.
    Hardee JP; Montalvo RN; Carson JA
    Oxid Med Cell Longev; 2017; 2017():8018197. PubMed ID: 29375734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basic and translational research: from molecule, to mouse, to man.
    Adams V; Möbius-Winkler S; Schuler G
    Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16 Suppl 2():S48-52. PubMed ID: 19675437
    [No Abstract]   [Full Text] [Related]  

  • 19. Molecular mechanism of sarcopenia and cachexia: recent research advances.
    Sakuma K; Aoi W; Yamaguchi A
    Pflugers Arch; 2017 Jun; 469(5-6):573-591. PubMed ID: 28101649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The biological mechanisms of cancer-related skeletal muscle wasting: the role of progressive resistance exercise.
    Al-Majid S; Waters H
    Biol Res Nurs; 2008 Jul; 10(1):7-20. PubMed ID: 18705151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.